Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.36 |
| ▸ | DPP4 | P27487 | 5/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13314435 | 1.00 | GSR (0.50) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL13314437 | 0.95 | GSR (0.42) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL29410188 | 0.82 | GSR (0.46) | GSRSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL28945063 | 0.82 | GSR (0.46) | GSRSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3275066 | 0.80 | GSR (0.52) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL20945414 | 0.80 | GSR (0.52) | GSRGNAI3GNAO1GNAI1DPP7 | |
| Hydrochloric Acid SCHEMBL20945380 | 0.79 | GSR (0.50) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL21590082 | 0.78 | SLC1A3 (0.38) | SLC1A3SLC1A2SLC1A1NPC1 | |
| SCHEMBL21590074 | 0.78 | SLC1A3 (0.38) | SLC1A3SLC1A2SLC1A1NPC1 | |
| SCHEMBL1003011 | 0.77 | GSR (0.57) | GSRGNAI3GNAO1GNAI1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119789876-A | Method of modifying organic cytotoxins for use as payloads in antibody-drug conjugates and modified organic cytotoxins derived therefrom | 辛利斯生物制药有限责任公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11497757-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-11291731-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20210356377-A1 | Methods Of Cell Selection | MEDIMMUNE, LLC | 2021-11-18 | — | — | US | disclosed |
| EP-3847271-A1 | METHODS OF CELL SELECTION | MedImmune, LLC (US) | 2021-07-14 | — | — | EP | disclosed |
| CN-112673109-A | Cell selection method | 免疫医疗有限责任公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-110724707-A | Novel nucleic acid molecules | 米迪缪尼有限公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-105247049-B | novel nucleic acid molecules | 米迪缪尼有限公司 | 2019-09-13 | — | — | CN | disclosed |
| WO-2014044872-A1 | CELL LINES | ALLOZYNE, INC (US) | 2014-03-27 | — | — | WO | disclosed |
| EP-2670767-A1 | UNNATURAL AMINO ACIDS COMPRISING A CYCLOOCTYNYL OR TRANS-CYCLOOCTENYL ANALOG GROUP AND USES THEREOF | EMBL (DE) | 2013-12-11 | — | — | EP | disclosed |
| US-20120316078-A1 | METHODS AND MATERIALS FOR PRODUCING POLYPEPTIDES IN VITRO | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2012-12-13 | — | — | US | disclosed |
| WO-2012104422-A1 | UNNATURAL AMINO ACIDS COMPRISING A CYCLOOCTYNYL OR TRANS-CYCLOOCTENYL ANALOG GROUP AND USES THEREOF | EMBL (DE) | 2012-08-09 | — | — | WO | disclosed |
| US-20120065123-A1 | Synthetic Antibodies | NATIONAL INSTITUTES OF HEALTH | 2012-03-15 | — | — | US | disclosed |
| US-20120021967-A1 | SYNTHETIC ANTIBODIES | Arizona Board of Regents, A Body Corporate of the State Of Arizona Acting for and Behalf of Arizona (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2011106106-A2 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH HEPADNAVIRIDAE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106573-A2 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH HEPADNAVIRIDAE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | disclosed |
| WO-2010111299-A2 | SYNTHETIC ANTIBODIES | THE ARIZONA BOARD OF REGENTS A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2009140039-A2 | SYNTHETIC ANTIBODIES | THE ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11497757-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | GSR 3223/4885GNAI3 3156/4885GNAO1 2841/4885 |
| US-11291731-B2 | Silicon based drug conjugates and methods of using same | CD44, MSN, AS3MT | GSR 2365/4885GNAI3 3853/4885GNAO1 4186/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | GSR 2365/4885GNAI3 3853/4885GNAO1 4186/4885 |
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | CD47, CD4, BST2 | GSR 3223/4885GNAI3 3156/4885GNAO1 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.